Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
ESRD (End-Stage Renal Disease): early-phase trial registry
3 of 4 indexed ESRD (End-Stage Renal Disease) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
ESRD (End-Stage Renal Disease): 4 US clinical trials tracked, 3 recruiting.
ESRD (End-Stage Renal Disease) is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is United Therapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition esrd-end-stage-renal-disease
OPEN 3 | RECR 75% | LATE 1 | EARLY 3 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
ESRD (End-Stage Renal Disease) lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for ESRD (End-Stage Renal Disease) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
ESRD (End-Stage Renal Disease) is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
Alebund Pharmaceuticals
NCT06933472
Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD
United Therapeutics
NCT06878560
Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD
United Therapeutics
NCT07224763
A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment
Bristol-Myers Squibb
NCT02902679
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on ESRD (End-Stage Renal Disease) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on ESRD (End-Stage Renal Disease) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this ESRD (End-Stage Renal Disease) page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 ESRD (End-Stage Renal Disease) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- United Therapeutics sponsors the most ESRD (End-Stage Renal Disease) trials on record, review their full trial history before evaluating a specific study. See United Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This ESRD (End-Stage Renal Disease) condition card totals 4 registered trials; most-linked intervention BMS-986177; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.